Development of anti-cancer therapy combined with cyclooxygenase-2 inhibitors

环加氧酶2抑制剂联合抗癌疗法的开发

基本信息

  • 批准号:
    17590639
  • 负责人:
  • 金额:
    $ 1.98万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

Background & Aims : Cyclooxygenase-2 (COX-2) inhibitors are effective chemopreventive agents against colorectal cancers. For treatment of advanced cancers, combination of COX-2 inhibitors and chemotherapy has been attempted, but the results are still controversial. In the present study, the effects of the COX-2 inhibitor celecoxib on the anticancer potential of chemotherapy, and its mechanisms of action were investigated in point of the angiogenesis and the immune response using an advanced cancer model in mice.Methods : BALB/c mice or BALB/c IFN-γ null mice were inoculated with colon 26 cells. After the allograft grew up to 5mm in diameter, the animals received celecoxib (3mg/kg), 5FU (20mg/kg), or a combination of 5FU and celecoxib (5FU/celecoxib). After 21-days of the treatment, tumors were harvested and used for analyzing angiogenesis (expression of CD31) or leukocyte infiltration (CD45 expression) by immunohistochemistry and for measuring VEGF, IFN-γ concentration by ELISA. The fr … More equency of infiltrating immune cells in the tumors was also analyzed by flow cytometric analyses.Result s: 5FU/celecoxib significantly inhibited the tumor growth and the tumor vessel density compared with the other groups. Celecoxib, 5FU or 5FU/celecoxib significantly suppressed the VEGF content in tumor tissues. 5FU/celecoxib also enhanced IFN-γ levels in tumor tissue, which could be involved in the potent antitumor effects of 5FU/celecoxib. This hypothesis was proven, because in IFN-γ null mice, the inhibitory effects of 5FU/celecoxib on angiogenesis and tumor growth were significantly impaired compared with that in wild type mice. 5FU decreased leukocyte infiltration and increased CD4+CD25^<high> T cell frequency, but the addition of celecoxib reversed these 5FU treatment related effects. 5FU and 5FU/celecoxib increased frequency of matured dendritic cells in the tumors compared with control.Conclusion : These results suggest that celecoxib enhances the antitumor effect of 5FU against an advanced colon cancer model by suppressing angiogenesis and enhancing the immune response against the tumor. In addition to VEGF, IFN-γ has pivotal roles in tumor suppression induced by a COX-2 inhibitor. Less
背景与目的:环氧合酶-2(考克斯-2)抑制剂是有效的结直肠癌化学预防剂。对于晚期癌症的治疗,已经尝试了考克斯-2抑制剂和化学疗法的组合,但结果仍有争议。本研究采用小鼠晚期肿瘤模型,从肿瘤血管生成和免疫应答两方面探讨了考克斯-2抑制剂塞来昔布对化疗的抗癌作用及其机制。当同种异体移植物生长至直径为5 mm时,动物接受塞来昔布(3 mg/kg)、5 FU(20 mg/kg)或5 FU和塞来昔布的组合(5 FU/塞来昔布)。治疗21天后,收获肿瘤并通过免疫组织化学分析血管生成(CD 31表达)或白细胞浸润(CD 45表达),并通过ELISA测量VEGF、IFN-γ浓度。的fr ...更多信息 结果:5 FU/Celecoxib组肿瘤生长明显抑制,肿瘤血管密度明显降低,与其他组比较差异有统计学意义(P < 0. 05)。塞来昔布、5 FU或5 FU/塞来昔布均能显著抑制肿瘤组织中VEGF的含量。5 FU/塞来昔布还可增强肿瘤组织中IFN-γ的水平,这可能与5 FU/塞来昔布的强效抗肿瘤作用有关。这一假设得到了证实,因为在IFN-γ敲除小鼠中,与野生型小鼠相比,5 FU/塞来昔布对血管生成和肿瘤生长的抑制作用显著受损。5 FU可减少白细胞浸润,增加CD 4 + CD 25 ^<high>T细胞频率,但加入塞来昔布可逆转这些5 FU治疗相关效应。5 FU和5 FU/塞来昔布增加了肿瘤中成熟树突状细胞的频率与control.Conclusion相比:这些结果表明,塞来昔布通过抑制血管生成和增强对肿瘤的免疫应答来增强5 FU对晚期结肠癌模型的抗肿瘤作用。除VEGF外,IFN-γ在由考克斯-2抑制剂诱导的肿瘤抑制中具有关键作用。少

项目成果

期刊论文数量(37)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Combination of enprostil and cimetidine is more effective than cimetidine alone in treating gastric ulcer : prospective multicenter randomized controlled trial.
恩前列素和西咪替丁联合治疗胃溃疡比单独使用西咪替丁更有效:前瞻性多中心随机对照试验。
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Murata H;Kawano S;Tsuji S;Tsujii M;Hori M;Kamada T;Matsuzawa Y;Katsu K;Inoue K;Kobayashi K;Mitsufuji S;Bamba T;Kawasaki H;Kajiyama G;Umegaki E;Inoue M;Saito I
  • 通讯作者:
    Saito I
Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-γ
  • DOI:
    10.1002/ijc.22720
  • 发表时间:
    2007-08-15
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
    Irie, Takanobu;Tsujii, Masahiko;Hayashi, Norio
  • 通讯作者:
    Hayashi, Norio
Geranylgeranylacetone induces cyclooxygenase-2 expression in cultured rat gastric epithelial cells through NF-kappaB.
香叶基香叶基丙酮通过 NF-kappaB 诱导培养的大鼠胃上皮细胞中环氧合酶 2 的表达。
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Nishida T;Yabe Y;Fu HY;Hayashi Y;Asahi K;Eguchi H;Tsuji S;Tsujii M;Hayashi N;Kawano S.
  • 通讯作者:
    Kawano S.
(2E,6Z,10E)-7-hydxoxymethyl-3,11,15-trimethyl-2,6,10,14-hex adecatetraen-1-ol (Plaunotol) increases cyclooxygenase-2 expression via nuclear factor kappaB and cyclic AMP response element in rat gastric epithelial cells.
(2E,6Z,10E)-7-hydxoxymethyl-3,11,15-trimethyl-2,6,10,14-hex adecatetraen-1-ol (Plaunotol) 通过核因子 kappaB 和环 AMP 反应增加 cyclooxygenase-2 表达
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fu H;Yabe Y;Asahi K;Hayashi Y;Murata H;Eguchi H;Tsujii M;Tsuji S;kawano S
  • 通讯作者:
    kawano S
Juvenile hepatocellular carcinoma with congestive liver cirrhosis
  • DOI:
    10.1007/s00535-004-1525-4
  • 发表时间:
    2005-02-01
  • 期刊:
  • 影响因子:
    6.3
  • 作者:
    Izumi, Y;Hiramatsu, N;Hayashi, N
  • 通讯作者:
    Hayashi, N
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TSUJII Masahiko其他文献

TSUJII Masahiko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TSUJII Masahiko', 18)}}的其他基金

Crosstalk between CagA and inflammation in H. pylori-related gastric carcinogenesis.
CagA 与幽门螺杆菌相关胃癌发生中炎症之间的串扰。
  • 批准号:
    24659365
  • 财政年份:
    2012
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Development of biomarkers using cancer cells derived from clinical samples
使用来自临床样本的癌细胞开发生物标志物
  • 批准号:
    24390188
  • 财政年份:
    2012
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Investigation of the effects of CagA on phenotype using microRNA array analysis
使用 microRNA 阵列分析研究 CagA 对表型的影响
  • 批准号:
    21590788
  • 财政年份:
    2009
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of target molecules involved in enhanced antitumoreffects of chemotherapy for colorectal cancer from the view point of tumor immunity andtumor angiogenesis.
从肿瘤免疫和肿瘤血管生成的角度研究增强结直肠癌化疗抗肿瘤作用的靶分子。
  • 批准号:
    19590722
  • 财政年份:
    2007
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of effective combinational chemopreventive therapies modulating IGF-1 receptor as a molecular target
开发以 IGF-1 受体为分子靶标的有效联合化学预防疗法
  • 批准号:
    15590644
  • 财政年份:
    2003
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Cyclooxy genase-2 Activity Altered the Cell-Surface Carbohydrate Antigens on. Colon. Cancer Cells and Enhanced Liver Metastasis
环氧化酶 2 活性改变了细胞表面碳水化合物抗原。
  • 批准号:
    13670514
  • 财政年份:
    2001
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

I-Corps: Translation potential of using machine learning to predict oxaliplatin chemotherapy benefit in early colon cancer
I-Corps:利用机器学习预测奥沙利铂化疗对早期结肠癌疗效的转化潜力
  • 批准号:
    2425300
  • 财政年份:
    2024
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Standard Grant
Targeting cancer stem-like cells and inflammation for colon cancer chemoprevention
针对癌症干细胞样细胞和炎症进行结肠癌化学预防
  • 批准号:
    10650910
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Bacteria-derived xenobiotics in colon cancer prevention: Link to GPR109A and colonic ketogenesis
细菌源性异生素在结肠癌预防中的作用:与 GPR109A 和结肠生酮的联系
  • 批准号:
    10737017
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Generation of chimeric antigen receptor T cells using antibodies derived from colon cancer tumor-associated B cells.
使用源自结肠癌肿瘤相关 B 细胞的抗体生成嵌合抗原受体 T 细胞。
  • 批准号:
    23K15473
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Enteric Glia is New Biological Target to Block Drug Resistance in Colon Cancer
肠胶质细胞是阻断结肠癌耐药性的新生物靶点
  • 批准号:
    10659846
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Mechanisms and strategies to rescue suboptimal T cell priming in colon cancer
挽救结肠癌 T 细胞启动不良的机制和策略
  • 批准号:
    10644249
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Novel Tools for Colon Cancer Detection and Therapy
结肠癌检测和治疗的新工具
  • 批准号:
    10480318
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTION
进一步开发基于 IPSC 的结肠癌预防疫苗
  • 批准号:
    10893658
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
Precision medicine tool for informing the treatment of colon cancer in minutes
精准医疗工具可在几分钟内告知结肠癌的治疗
  • 批准号:
    10054824
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Collaborative R&D
Breeding of rice with increased the content of glucosylceramide, which improves skin barrier function and prevents colon cancer
培育出增加葡萄糖神经酰胺含量的大米,可改善皮肤屏障功能并预防结肠癌
  • 批准号:
    23K05119
  • 财政年份:
    2023
  • 资助金额:
    $ 1.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了